<DOC>
	<DOC>NCT01159730</DOC>
	<brief_summary>The purpose of this study is to assess the safety and tolerability of multiple doses of VB-201 administered for 4 weeks and its efficacy on biomarkers.</brief_summary>
	<brief_title>Study to Assess the Safety and Efficacy of Multiple Doses of VB-201 on Biomarkers</brief_title>
	<detailed_description />
	<criteria>Male or female patients, ≥18 to ≤75 years of age; Presence of, or history of cancer, with the exception of completely excised, nonmetastatic squamous cell or basal cell carcinomas of the skin; Has a clinically significant systemic infection (e.g., chronic or acute infection, UTI, URI) within 30 days of Day 0, or a history or presence of recurrent or chronic infection (e.g. viral infections, [including hepatitis B or C, HIV], bacterial infections, systemic fungal infections, or syphilis); Subjects with a history of coronary events within the last 6 months;</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>November 2011</verification_date>
</DOC>